Expert Interview
Alnylam’s AMVUTTRA (Vutrisiran) in ATTR Amyloidosis: Cardiomyopathy & Polyneuropathy Market Outlook
Ticker(s): ALNYA geneticist with experience in helping people with hATTR Amyloidosis.
5% of the patients with primary amyloidosis survive beyond 10 years. Have you had such success stories in your patients, and what would you attribute that to? What percent of patients can go into remission with drug therapy?
Can you talk to us more about the potential of RNAi therapeutics like Vutrisiran, where do you see them standing in the near future? What is the likelihood of reducing deposition and cleaning of TTR amyloid deposits in tissues?
Alnylam boasts about increased potency and high metabolic stability, that would allow for infrequent subcutaneous injections. How much would that weigh in the balance when deciding on a treatment course for your patients?
Could you please discuss the HELIOS-A 18-Month Study Results, posted on Jan 21, treported cardiac improvement when taking vutrisiran?
Added By: slingshot_insights- How important is the promise that most patients will pay $0 out-of-pocket, with support from Alnylam Assist?
- Which patient types would you prioritize for treatment with AMVUTTRA?
- What gaps or unmet needs still exist in ATTR care, even with vutrisiran now approved for both indications?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
